Lumakras (sotorasib) / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...2122232425262728293031...3839»
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Review, Journal:  Spotlight on Sotorasib (AMG 510) for KRAS Positive Non-Small Cell Lung Cancer. (Pubmed Central) -  Oct 25, 2021   
    Many proposals have been made to address this, such as the use of combination therapy for synthetic lethality, which are producing encouraging results. Here, we explore in further detail the development of sotorasib, its efficacy, mechanism of resistance, and strategies to overcome these resistances.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Review, Journal:  Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. (Pubmed Central) -  Oct 25, 2021   
    Decades of unsuccessful experimentation had deemed Ras undruggable, but recently, the approval of Sotorasib as the first ever KRas inhibitor represents a monumental breakthrough...Furthermore, significant challenges in targeting downstream Raf, especially the BRaf isoform, lie in the paradoxical activation of wild-type BRaf by BRaf mutant inhibitors. This literature review will delineate the mechanisms of Ras signaling in the MAPK pathway and its possible oncogenic mutations, illustrate how specific mutations affect the pathogenesis of specific cancers, and compare available and in-development treatments targeting the Ras pathway.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal:  Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. (Pubmed Central) -  Oct 8, 2021   
    Finally, we show that a selective PI4KA inhibitor augments the antineoplastic activity of the KRAS inhibitor sotorasib, suggesting a clinical path to exploit this pathway. In sum, we have discovered a distinct KRAS signaling axis with actionable therapeutic potential for the treatment of KRAS-mutant cancers.
  • ||||||||||  adagrasib (MRTX849) / Mirati, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Adagrasib Data Create Buzz at ESMO. (Pubmed Central) -  Oct 6, 2021   
    Among patients who received the drug combination, the disease control rate was 100%; data on progression-free survival were immature. The findings, along with data on the KRAS inhibitor sotorasib, were presented at the 2021 European Society for Medical Oncology Congress.
  • ||||||||||  Biomarker, Journal, PD(L)-1 Biomarker, PD(L)-1 companion diagnostic:  Site-agnostic biomarker-guided oncology drug development. (Pubmed Central) -  Oct 6, 2021   
    With the recent approval of entrectinib, larotrectinib, and pembrolizumab for site-agnostic indications, biomarker-guided drug development has entered into a new phase...For a site-agnostic indication, it is important to have in mind the central role of the companion diagnostic (CDx), as the assay defines the "disease" and the patient population to be treated. A number of site-agnostic drugs are currently in development and here, it is important that CDx assay development is given high priority, so an analytical and clinical validated assay is available at the time of drug approval.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Enrollment closed:  Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants (clinicaltrials.gov) -  Oct 5, 2021   
    P1,  N=13, Active, not recruiting, 
    A number of site-agnostic drugs are currently in development and here, it is important that CDx assay development is given high priority, so an analytical and clinical validated assay is available at the time of drug approval. Recruiting --> Active, not recruiting
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal:  Sotorasib. (Pubmed Central) -  Oct 1, 2021   
    Recruiting --> Active, not recruiting No abstract available